To examine the time to healing of genital lesion and duration of herpes simplex virus (HSV) shedding from genetic ulcer disease (GUD) among 90 HIV-negative African women who have a history of GUD and are HSV-2 seropositive and HIV-1 seronegative randomized in a 2:1 ratio to receive episodic acyclovir 400mg orally three times daily or matching placebo three times daily for 5 days and who are followed for a total of 13 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
88
400mg taken orally three times daily for 5 days
matching placebo taken orally three times daily for 5 days.
Reproductive Health and HIV Research Unit (RHRU)
Johannesburg, South Africa
Center for Infectious Disease Research of Zambia (CIDRZ)
Lusaka, Zambia
Time to Healing of Genital Lesions
To examine time to healing of genital lesions among women who have a history of GUD and are HSV-2 seropositive and HIV-1 seronegative, and who are randomized to 400mg acyclovir or matching placebo
Time frame: Days 1-5, 7, 9, 11, 13
Time to First Negative Herpes Simplex Virus (HSV) DNA PCR
To examine the time to first negative HSV DNA PCR among women who have a history of GUD and are HSV-2 seropositive and HIV-1 seronegative, and who are randomized to 400mg acyclovir or matching placebo
Time frame: Days 1-5, 7, 9, 11, 13
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.